SCHEMBL2683449

SCHEMBL2683449

CC(C)[Si](O[C@@H]1CN([C@H](C)c2ccccc2)C[C@H](O)[C@H]1c1ccc(OCc2ccccc2)cc1)(C(C)C)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 1/20 0.42
ALOX5 P09917 2/20 0.38
MAOB P27338 1/20 0.37
MAPT P10636 2/20 0.36
BCHE P06276 2/20 0.36
REN P00797 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2338156 1.00 CHRM4 (0.42) CHRM4ALOX5MAOBMAPTBCHE
SCHEMBL1941951 0.78 CHRM4 (0.37) CHRM4ALOX5REN
SCHEMBL27456044 0.78 CHRM4 (0.37) CHRM4ALOX5REN
SCHEMBL2338146 0.77 MAOB (0.39) CHRM4ALOX5MAOBBCHENPC1
SCHEMBL2683456 0.77 MAOB (0.39) CHRM4ALOX5MAOBBCHENPC1
SCHEMBL2683457 0.77 MAOB (0.39) CHRM4ALOX5MAOBBCHENPC1
SCHEMBL4602232 0.77 CHRM4 (0.54) CHRM4ALOX5MAOBNPC1RAB9A
SCHEMBL27488557 0.77 CHRM4 (0.54) CHRM4ALOX5MAOBNPC1RAB9A
SCHEMBL6625512 0.77 CHRM4 (0.54) CHRM4ALOX5MAOBNPC1RAB9A
SCHEMBL4601018 0.77 CHRM4 (0.54) CHRM4ALOX5MAOBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115859-A1 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS HEROLD PETER (CH) 2012-05-10 US disclosed
US-20090270380-A1 3,4,5-Substituted Piperidines as Renin Inhibitors NOVARTIS AG (CH) 2009-10-29 US disclosed
US-20090029981-A1 SUBSTITUTED 4-PHENYLPIPERIDINES NOVARTIS AG (CH) 2009-01-29 US disclosed
EP-2018862-A1 Substituted piperidines as therapeutic compounds Speedel Experimenta AG (CH) 2009-01-28 EP disclosed
EP-1973903-A1 SUBSTITUTED 4-PHENYLPIPERIDINES Speedel Experimenta AG (CH) 2008-10-01 EP disclosed
EP-1908762-A2 Organic compounds Speedel Experimenta AG (CH) 2008-04-09 EP disclosed
EP-1908761-A1 Organic compounds Speedel Experimenta AG (CH) 2008-04-09 EP disclosed
EP-1863763-A1 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS Speedel Experimenta AG (CH) 2007-12-12 EP disclosed
EP-1816122-A2 3,4,5-substituted piperidines as therapeutic compounds Speedel Experimenta AG (CH) 2007-08-08 EP disclosed
WO-2007082907-A1 SUBSTITUTED 4-PHENYLPIPERIDINES SPEEDEL EXPERIMENTA AG (CH) 2007-07-26 WO disclosed
US-20070167433-A1 3,4,5-Substituted piperidines as therapeutic compounds SPEEDEL EXPERIMENTA AG (CH) 2007-07-19 US disclosed
WO-2006103275-A1 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS SPEEDEL EXPERIMENTA AG (CH) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167433-A1 3,4,5-Substituted piperidines as therapeutic compounds CTSD, CTSL, CTSZ CHRM4 2037/4885ALOX5 4669/4885MAOB 2859/4885
US-20120115859-A1 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS REN, AGTR1, AGTR2 CHRM4 534/4885ALOX5 3219/4885MAOB 681/4885
US-20090270380-A1 3,4,5-Substituted Piperidines as Renin Inhibitors REN, AGTR1, AGTR2 CHRM4 445/4885ALOX5 3335/4885MAOB 666/4885
US-20090029981-A1 SUBSTITUTED 4-PHENYLPIPERIDINES REN, AGTR2, ACE CHRM4 759/4885ALOX5 4478/4885MAOB 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.